Scarica l'app Stockscreener
7.59
0.26%
0.02
Dopo l'orario di chiusura:
7.47
-0.12
-1.58%
Precedente Chiudi:
$7.57
Aprire:
$7.6
Volume 24 ore:
1.56M
Relative Volume:
0.66
Capitalizzazione di mercato:
$1.23B
Reddito:
$181.41M
Utile/perdita netta:
$-59.56M
Rapporto P/E:
-18.07
EPS:
-0.42
Flusso di cassa netto:
$-38.83M
1 W Prestazione:
+3.97%
1M Prestazione:
+47.67%
6M Prestazione:
+102.40%
1 anno Prestazione:
+167.25%
Intervallo 1D:
$7.51
$7.73
Intervallo di 1 settimana:
$7.205
$7.79
Portata 52W:
$2.48
$7.79
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Nome
Xeris Biopharma Holdings Inc
Settore
Industria
Telefono
844-445-5704
Indirizzo
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Confronta XERS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
7.59 | 1.19B | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-12 | Ripresa | H.C. Wainwright | Buy |
| 2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2023-08-28 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Craig Hallum | Buy |
| 2021-11-17 | Iniziato | SVB Leerink | Outperform |
| 2021-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-02-18 | Iniziato | Piper Sandler | Overweight |
| 2018-07-16 | Iniziato | Jefferies | Buy |
| 2018-07-16 | Iniziato | Leerink Partners | Outperform |
| 2018-07-16 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Xeris Biopharma Holdings Inc Borsa (XERS) Ultime notizie
Johnson, director, sells Xeris Biopharma (XERS) shares for $786k - Investing.com
Johnson, director, sells Xeris Biopharma (XERS) shares for $786k By Investing.com - Investing.com Nigeria
Independent Director Dawn Halkuff Sold A Bunch Of Shares In Xeris Biopharma Holdings - simplywall.st
Can Xeris Biopharma Holdings Inc. expand its profit margins2025 Market Outlook & Precise Swing Trade Alerts - sundaytimes.kr
Tools to assess Xeris Biopharma Holdings Inc.’s risk profile2025 Earnings Impact & Weekly High Potential Stock Alerts - Newser
Is Xeris Biopharma Holdings Inc. stock a good dividend stockQuarterly Portfolio Report & Stock Portfolio Risk Control - thegnnews.com
Will Xeris Biopharma Holdings Inc. benefit from macro trendsMarket Performance Recap & Capital Efficiency Focused Ideas - Newser
Insider Selling at Xeris Biopharma: A Signal or a Strategy? - AInvest
Xeris Biopharma Director Dawn Halkuff Sells 42,500 Shares at $7.28 Each. - AInvest
Xeris Biopharma (NASDAQ:XERS) Upgraded at HC Wainwright - Defense World
Dawn Halkuff sells Xeris Biopharma (XERS) shares worth $309k By Investing.com - Investing.com Nigeria
Dawn Halkuff sells Xeris Biopharma (XERS) shares worth $309k - Investing.com
Xeris Biopharma (NASDAQ:XERS) Raised to “Buy” at HC Wainwright - Defense World
How high can Xeris Biopharma Holdings Inc. stock goDollar Strength & Entry and Exit Point Strategies - Newser
Xeris Biopharma (NASDAQ:XERS) Coverage Initiated by Analysts at HC Wainwright - Defense World
Using Python tools to backtest Xeris Biopharma Holdings Inc. strategiesReal Time Stock Movement and Alerts - Newser
Xeris Biopharma (XERS) Upgraded to Buy: Here's Why - Yahoo Finance
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Xeris Biopharma Earns Buy Rating from HC Wainwright with $10 PT - AInvest
Can trapped investors hope for a rebound in Xeris Biopharma Holdings Inc.Momentum Prediction Based on AI Backtesting - Newser
How liquid is Xeris Biopharma Holdings Inc. stockSpeedy Gain Trade Picks - thegnnews.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
Wyckoff Accumulation Phase Possible in Xeris Biopharma Holdings Inc.Potential Breakout Stock List Published This Week - beatles.ru
Bollinger Bands Show Potential Breakout in Xeris Biopharma Holdings Inc.Day Trading Signals With High Precision Reviewed - beatles.ru
How Xeris Biopharma Holdings Inc. stock performs during market volatilityForecast Model for Intraday Buy Signals - Newser
Xeris Biopharma Holdings Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2025 Earnings Call Transcript - Insider Monkey
Xeris Biopharma (NASDAQ:XERS) Sees Large Volume Increase Following Better-Than-Expected Earnings - Defense World
Xeris Biopharma (NASDAQ:XERS) Upgraded to “Strong-Buy” at Wall Street Zen - Defense World
Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - NewsBreak: Local News & Alerts
XERS (Xeris Biopharma Holdings) Momentum Rank : 3 (As of Aug. 08, 2025) - GuruFocus
XERS Crosses Above Average Analyst Target - Nasdaq
Xeris Biopharma Reports Record Q2 2025 Revenue, Raises Full-Year Guidance - AInvest
Xeris Biopharma: Q2 Earnings Snapshot - Connecticut Post
Xeris Biopharma (NASDAQ:XERS) Sets New 52-Week High Following Earnings Beat - Defense World
Xeris Biopharma Reports Strong Q2 2025 Results - TipRanks
Beyond the Balance Sheet: What SWOT Reveals About Xeris Biopharm - GuruFocus
Xeris raises 2025 revenue guidance to $280M–$290M following 49% Q2 growth, led by Recorlev - MSN
Xeris Biopharma Holdings, Inc. SEC 10-Q Report - TradingView
Transcript : Xeris Biopharma Holdings, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Xeris Biopharma Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Little Excitement Around Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Revenues - 富途牛牛
Xeris (XERS) Q2 Revenue Jumps 49% - The Motley Fool
Xeris Biopharma shares rise 24.23% premarket after beating Q2 revenue expectations and raising FY guidance. - AInvest
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Xeris Biopharma Stock Soars 12.02% on Record Q2 Earnings - AInvest
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance - BioSpace
Earnings Flash (XERS) Xeris Biopharma Posts Q2 Net Loss $0.01 a Share, vs. FactSet Est of $0.05 Loss - MarketScreener
Xeris Biopharma beats Q2 revenue expectations, raises FY guidance - MarketScreener
Mackenzie Financial Corp Has $780,000 Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Institutional scanner results for Xeris Biopharma Holdings Inc.Trade Flow Monitor with Volume Tracker - Newser
Xeris Biopharma Holdings Inc Azioni (XERS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xeris Biopharma Holdings Inc Azioni (XERS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HALKUFF DAWN | Director |
Aug 12 '25 |
Sale |
7.28 |
42,500 |
309,226 |
115,000 |
1.55%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):